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Within the last few years the field personalized medicine entered the stage. Accompanied
with great hopes and expectations it is believed that this field may have the potential
to revolutionize medical and clinical care by utilizing genomics information about the
individual patients themselves. In this paper, we reconstruct the early footprints of
personalized medicine as reflected by information retrieved from PubMed and Google
Scholar. That means we are providing a data-driven perspective of this field to estimate its
current status and potential problems.
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INTRODUCTION
The HUMAN GENOME PROJECT (Lander et al., 2001; Venter
et al., 2001; Consortium, 2004) did not only result in the first
sequencing of the human DNA but it also fostered technologi-
cal advances exploitable beyond its initial purpose (Quackenbush,
2011). As a result from such technologies a variety of differ-
ent types of “Omics” data (Ghosh and Poisson, 2009; Moreno-
Risueno et al., 2010), e.g., genomics, transcriptomics, proteomics,
metabolomics, and epigenomics data (Lee et al., 2002; Förster
et al., 2003; Rual et al., 2005; Stelzl et al., 2005; Palsson, 2006;
Sechi, 2007; Garbett et al., 2008; Yu et al., 2008) can nowadays be
generated to measure molecular entities on all relevant biological
levels. With respect to a medical application these technolo-
gies generated an immediate impetus on the field personalized
medicine because it aims to integrate genomics and clinical data
from individual patients in order to improve patient care by iden-
tifying more efficient treatment strategies (Auffray et al., 2009;
Ginsburg andWillard, 2009; Hamburg and Collins, 2010; Fernald
et al., 2011).
In this paper we present a data-driven overview of the early his-
tory of personalizedmedicine. We are using information retrieved
from PubMed and Google Scholar to obtain quantitative infor-
mation statistics of published articles and the community struc-
ture of scientists that share a common interest in this topic. From
this information we try to identify the potential impact person-
alized medicine has made so far but also to reveal indicators of
problems that might prevent its blossoming. Despite the fact that
PubMed and Google Scholar provide a wealth of curated data
about various aspects of published articles over the last decades
and the research interests of thousands of scholars it should be
emphasized that neither has been designed to serve the purpose
of our analysis. For this reasons, the drawn conclusions should
only be seen as an indicator. Nevertheless, utilizing databases like
PubMed and Google Scholar allows to present arguments beyond
a mere opinion due to the possibility to compare different aspects
quantitatively with each other.
Specifically, to allow for a simplified interpretation of the
retrieved numbers from PubMed and Google Scholar we present
whenever appropriate a comparison with related topics. For
example, rather than presenting an interpretation based on abso-
lute numbers of, e.g., published research papers and review or
editorial papers published for personalized medicine we perform
a similar analysis for related fields like bioinformatics and systems
biology and present a comparative interpretation. This relieves us
from the burden to introduce to many ad hoc assumptions that
may lead to erroneous interpretations if they would be too far-off
the truth.
CURRENT STATE OF PERSONALIZED MEDICINE
In order to obtain a general overview of the current state of
the field personalized medicine we extract information from the
literature. Specifically, we are using information provided by
PubMed and compare publications in personalized medicine to
other fields. Further, we investigate also the content of such
publications, as far as this information is provided by PubMed.
For our following analysis we used the tool FLINK provided by
the NCBI. FLink allows to perform a conventional PubMed search
with the additional feature that the results can be downloaded as a
csv file. The obtained csv files are than parsed by scripts we wrote
in the statistical programming language R. The advantage of this
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approach is that we have convenient access to the same informa-
tion that is visually represented by a conventional PubMed search
but can process this information as desired. For the following
analysis we retrieved all data in November 2012.
We start by showing in Figure 1A the number of publi-
cations per year in computational biology (blue), genomics
(red), bioinformatics (orange), systems biology (purple), trans-
lational research (sky blue), and personalized medicine (green).
We selected these fields because they are closely related to
personalized medicine. From these curves one can see that per-
sonalized medicine emerged very recent in the literature becom-
ing notable only around 2005, which makes it the newest of all
shown fields with a steep increase within the recent 5 years. More
established fields like computational biology and genomics seem
to have peaked already by having reached their maxima.
Next, we try to get an insight into the distribution of research
papers and non-research papers from the listed PubMed publi-
cations. Specifically, we define as “non-research” papers review,
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FIGURE 1 | (A) Number of PubMed publications. (B) Distribution of
publications of the two categories “research paper” (blue) and “non-research
paper” (red). (C) Distribution for conjugated searches. Orange corresponds to
publications containing the search terms “personalized medicine” and
“topic” (on the x-axis) and purple corresponds to all remaining publications.
(D) Distribution of genomics data types, shown on the x-axis. (E) People
interested in personalized medicine are also interested in the topics on the
x-axis. (F) Numbers of scholar interested in the listed topics.
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comment and editorial articles and as research papers we define
all remaining articles. Figure 1B shows the distributions over
these two categories for the same six fields as in Figure 1A,
namely, computational biology (compbio), genomics, bioinfor-
matics (bioinfo), systems biology (sysbio), translational research
(transl res), and personalized medicine (pers med).
The red proportion in each bar corresponds to the percent-
age of publications that are non-research papers, whereas the blue
proportion corresponds to all other publication types. From a
comparison of the results one finds that in translational research
and in personalized medicine there is a larger percentage of
publications devoted to strategic and conceptual questions as rep-
resented by review articles, comments or editorial papers and a
smaller proportion of publications corresponds actually to orig-
inal research papers. This could be a reflection of the novelty of
these fields and the hopes that accompanies them. For this reason
there may be a higher proportion of articles that try to pave the
way for these fields, instead of actually contributing new results
either from experimental or computational work.
In general, personalized medicine has been conceived as a
way to improve medical and clinical patient care by taking into
account patient specific data. Hence, personalized medicine is
inherently connected to a clinical application. In Figure 1C, we
show the results of conjugated PubMed searches by querying
“personalized medicine” and one additional keyword, as given
on the x-axis of this Figure. From left to right: clinical, thera-
peutic, drug, biomarkers (biomark), public health (pub health),
and computational (comp). In Figure 1C the orange propor-
tion corresponds to the publications that contain both search
terms, whereas the purple proportion corresponds to all remain-
ing publications. The first three keywords (clinical, therapeutic,
and drug) are frequently present, as could be expected from the
purpose of personalized medicine. In contrast, the term “pub-
lic health” is not frequently present. This is plausible because
personalized medicine is on the level of an individual of a pop-
ulation, whereas public health investigates the population as a
whole.
It is somewhat surprising to see that the terms “biomarkers”
and “computational” are not frequently present either. This is sur-
prising because personalized medicine is data-driven and these
data are analyzed by computational methods aiming to identify
important signatures, e.g., in form of biomarkers. A possible rea-
son for the underrepresentation of these terms could be again
given by the novelty of this field, as discussed for Figure 1A.
Another explanation could be the underappreciation of com-
putational methods. That means these methods could be used,
however, without appropriately describing them in the methods
section of publications which would almost inevitably require the
authors to use the term “computational.” Third, there could be
even another reason for this. Specifically, there could be exper-
imental studies that conduct genetics or genomics experiments
without actually conducting research one would identify as per-
sonalized medicine, but instead, the authors connect their results
to this field either in the introduction or the conclusion section
of a publication. Unfortunately, PubMed does not provide infor-
mation about the individual sections of a publication that would
allow to zoom-in in more detail.
DIVERSITY OF UTILIZED GENOMICS DATA
In order to obtain a general overview of the used genomics
data types that occur in any publication type, including origi-
nal research, review and editorial articles, related to personalized
medicine, we use again PubMed and search for conjugated hits,
i.e., “personalized medicine” and “term,” whereas the queries for
“term” correspond to the x-axis in Figure 1D. More precisely,
to capture a similar meaning of slightly different terms we also
include variations of these terms. For instance we count publica-
tions that include “next generation” as well as “next-generation.”
It is not surprising that “sequencing” surmounts all other
terms because it is the prototype technology to obtain genetic
information about various aspects of the DNA (Mardis, 2008;
Shendure and Ji, 2008; Ansorge, 2009). More surprising is to see
that “gene expression” and “proteomics” appear also quite fre-
quently in publications. It is reassuring to see this trend because
the DNA represents only static information about the state of
a cell whereas transcriptomics and proteomics data are capa-
ble of reflecting the dynamic state of molecular activity. For
this reason it is likely that information about the DNA alone
is not sufficient to accomplish the noble goals of personalized
medicine.
COMMUNITY STRUCTURE OF PERSONALIZED MEDICINE
Due to the multidisciplinarity of personalized medicine it would
be interesting to know what other interests people have that
are interested in personalized medicine. In order to answer this
question we are using Google Scholar.
In Figure 1E we show a histogram over fields that are listed on
the Google Scholar pages of scientists that have an interest in per-
sonalized medicine. Specifically, at the time of the analysis there
were 50 people that used the term “personalized medicine” to
indicate their interests. From parsing the Google Scholar pages
of these 50 individuals by using an R script we developed, we
determined the frequency of further interests listed by these schol-
ars. For example, among the 50 people interested in personalized
medicine, 14 are also interested in bioinformatics and 8 in systems
biology.
Figure 1E shows only the top 9 research interests of the 50 indi-
viduals. In total we found 95 different interest terms that have
been listed. There are three interesting observations that follow
from this figure. First, among the top 9 fields are many “compu-
tational” disciplines like bioinformatics, computational biology,
or machine learning. This supports the intuitive understanding of
personalizedmedicine described above that computational meth-
ods are a key means to approach this field practically. Second, the
dominance of computational methods in the top ranked fields
implies an underrepresentation of experimental fields as repre-
sented by genomics or cancer genomics. Interestingly, looking
further down the line to lower ranked research interests we find
a more balanced distribution of computational and experimen-
tal interests including, e.g., molecular genetics, medical oncology,
whole genome sequencing, or clinical trials. Hence, overall indi-
viduals interested in personalized medicine come from both
directions. Third, comparing the number of scholars we found
for personalized medicine with that of other subjects, as shown
in Figure 1F, we see that the community of scientists subscribing
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to personalized medicine is rather small. This corresponds to the
results in Figure 1A indicating that the field is barely beyond its
infancy.
CONCLUSION
It is without a doubt that the principle idea behind personal-
ized medicine holds a great potential for translational medicine
by improving diagnostic, prognostic and therapeutic approaches
for patient care. However, besides the seminal work of Chen et al.
(2012) only relatively few studies have been conducted in a similar
manner.
A principal hurdle for a wider and active engagement of the
community in this research area is certainly provided by the still
considerable costs incurred by the needed patient-based high-
throughput experiments. This is despite the steadily declining
costs for DNA sequencing.More important, I think that themajor
problem is a lack of a precise definition of personalized medicine
that would allow an efficient experimental design translating the
paradigm into practice.
Overall, based on the information we retrieved from PubMed
and Google Scholar we think that it is fair to say that personalized
medicine is still at the very beginning. It is increasingly recognized
within the literature, but a wider impact hasn’t been achieved yet.
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